RESUMO
INTRODUCTION: Spain is the country with the highest number of health care workers affected by coronavirus disease 2019 (COVID-19) in the world. The aim of this study was to describe the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection in health care worker (HCW) at the Gómez Ulla Military Hospital (HCDGU). MATERIALS AND METHODS: A case-control study was conducted during the first outbreak of COVID 19 at GUMH. The study was extended to the total number of HCW in the hospital who met the inclusion criteria. Health care worker of the HCDGU were civilian and military personnel that included nursing and medicine students of Spanish Military Academy, medicine specialty residents, and nursing residents of Medical Surgical Specialty in Operations (EMQO). A questionnaire of 33 items was prepared. The questionnaire was sent by e-mail to the entire population of study. With this questionnaire personnel were classified into sick (cases) or healthy. RESULTS AND CONCLUSIONS: One hundred fifty professionals answered the questionnaire. Cases were defined as those who tested positive in the diagnostic tests (n = 28, 20.7%) and no cases were those who tested negative (n = 107, 79.3%). Therefore, the percentage of SARS-CoV-2 in the GUMH was 20.7%. Of the total number of cases, 64.3% were men (P < .05), with a mean age of 47.1 years (SD 13.3), a mean BMI of 25.3 (SD 3.8), and 48.2% being overweight. Of the total cases, 59.3% had "A" blood group type and 69.2% were Rh positive. 50% were physicians, 32.1% were nurses, and 17.9% were auxiliary nurses (P < .05). Cases and controls with vitamin D deficiency and who took supplements had a lower risk of suffering COVID-19, with significant differences. Fever, cough, and diarrhea were found in at least 50% of the samples with significant differences.
Assuntos
COVID-19 , Masculino , Estados Unidos , Humanos , Pessoa de Meia-Idade , Feminino , COVID-19/epidemiologia , SARS-CoV-2 , Hospitais Militares , Estudos de Casos e Controles , Pessoal de Saúde , Inquéritos e Questionários , Atenção à SaúdeRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en septiembre, octubre y noviembre de 2017. Se trata de opiniones técnicas positivas previas a la autorización y puesta en el mercado del medicamento
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in September, October and November of 2017, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product
Assuntos
Aprovação de Drogas , Avaliação de Medicamentos , Preparações Farmacêuticas/administração & dosagem , Denominação Comercial do MedicamentoRESUMO
Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en marzo, abril y mayo 2017, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in March, April and May of 2017, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Aprovação de Drogas/estatística & dados numéricos , Avaliação de Medicamentos/tendências , Drogas em Investigação , Ensaios de Uso Compassivo , Terapia Biológica/estatística & dados numéricos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologiaRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en los meses de junio y julio de 2013, y considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in June and July of 2013, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Aprovação de Drogas , Medicamentos de Referência , Assistência FarmacêuticaRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el segundo trimestre de 2013, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
Medications are reviewed and evaluated by the Spanish Agency of Medicines and Health Products made public in the second quarter of 2013, and considered of greatest interest to the clinician. It is positive technical opinions that are pre-authorization and placing on the market of the product (AU)
Assuntos
Humanos , Drogas em Investigação , Avaliação de Medicamentos , Hormônio do Crescimento Humano , Fator VIII , Condrócitos , DextrometorfanoRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el primer trimestre de 2013, y considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the first quarter of 2013, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Desenho de Fármacos , Avaliação de Medicamentos , Medicamentos de Referência , Drogas em Investigação , Anticorpos MonoclonaisRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el último trimestre de 2012, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the last quarter of 2012, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Medicamentos de Referência , Drogas em InvestigaçãoRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios en el 3er trimestre de 2012, y considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the third quarter of 2012, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Avaliação de Medicamentos/estatística & dados numéricos , Drogas em Investigação/normas , Preparações Farmacêuticas , Ensaios Clínicos como AssuntoRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el segundo trimestre de 2012, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the second quarter of 2012, and con-sidered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Avaliação de Medicamentos/estatística & dados numéricos , Drogas em Investigação/normas , Preparações Farmacêuticas , Ensaios Clínicos como AssuntoRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el 1er trimestre de 2012, y considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the first trimester of 2012, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Drogas em Investigação/análise , Granisetron/uso terapêutico , Agonistas do Receptor de Serotonina/análise , Vacinas Meningocócicas/uso terapêutico , Somatostatina/uso terapêutico , Antraciclinas/uso terapêuticoRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el último trimestre de 2011, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the last quarter of 2011, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Drogas em Investigação , Medicamentos de Referência , Avaliação de Medicamentos , Uso de Medicamentos/legislação & jurisprudênciaRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el tercer trimestre de 2011, y considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the third quarter of 2011, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Drogas em Investigação , Antivirais/farmacologia , Antibacterianos/farmacologia , Hipoglicemiantes/farmacologia , Inibidores da Transcriptase Reversa/farmacologia , Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacologia , Antagonistas de Androgênios/farmacologiaRESUMO
Se reseñan los medicamentos ya evaluados por la A gencia E spañola de M edicamentos y Productos S anitarios hechos públicos en el segundo trimestre de 2011, y considerados de mayor interés para el profesional sanitario. S e trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the S panish A gency for M edicines and Health Products made public in the second quarter of 2011, and considered of interest to the healthcare professional, are reviewed. T hese are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Avaliação de Medicamentos , Drogas em Investigação , Ensaios Clínicos Fase I como AssuntoRESUMO
No disponible
Assuntos
Humanos , Melatonina/uso terapêutico , Síndrome do Jet Lag/tratamento farmacológico , 51708 , MilitaresRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el primer trimestre de 2011, y considerados de mayor interés para el profesional sanitario en el ámbito hospitalario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the first quarter of 2011, and considered of interest in hospital healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Medicamentos de Referência , Drogas em Investigação , Pesquisa Biomédica/tendênciasRESUMO
Se reseñan los medicamentos ya evaluados por la Agencia Española de Medicamentos y Productos Sanitarios hechos públicos en el último trimestre de 2010, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento (AU)
The drugs assessed by the Spanish Agency for Medicines and Health Products made public in the last quarter of 2010, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product (AU)
Assuntos
Humanos , Drogas em Investigação/farmacologia , Medicamentos de ReferênciaRESUMO
Como continuación de nuestro trabajo publicado con anterioridad de igual título como parte 1ª [Sanidad Militar 2007;64(2):118-127], presentamos el resto de fármacos que han sido comercializados en nuestro país durante el pasado año 2006, con atención a sus diversas características, algunas de ellas reflejadas en su ficha técnica, y otras comentadas para complementar su conocimiento (AU)
As a continuation of our previous article published with the same title as first part [Sanidad Militar 2007;64(2):118-127], we present the other drugs that have been commercialized in our country during 2006. They are presented in accordance with their different characteristics, some of them described in the technical data sheet and other commented in order to complement their knowledge. The active principles that we present in this second part represent, as has already been stated previously, a reduced contribution from the innovation point of view. However for certain patients or group of patients, and in concrete circumstances, they may represent a specific solution for a case that might have a worse outlook without this contribution. The drugs that we present in order to complete those commercialized during 2006 are the following (AU)
